Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Berberine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 10/20 | 0.98 |
| ▸ | CHRM1 known ✓ | P11229 | 2/20 | 0.98 |
| ▸ | BCHE | P06276 | 9/20 | 0.98 |
| ▸ | EP300 | Q09472 | 6/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.98 |
| ▸ | MAPT | P10636 | 4/20 | 0.98 |
| ▸ | RAD52 | P43351 | 4/20 | 0.98 |
| ▸ | LMNA | P02545 | 3/20 | 0.98 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.98 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.98 |
| ▸ | DRD2 | P14416 | 2/20 | 0.98 |
| ▸ | TSHR | P16473 | 2/20 | 0.98 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.98 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.98 |
| ▸ | RXRA | P19793 | 2/20 | 0.98 |
| ▸ | DRD1 | P21728 | 2/20 | 0.98 |
| ▸ | HTR2B | P41595 | 2/20 | 0.98 |
| ▸ | HTT | P42858 | 2/20 | 0.98 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.98 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Berberine SCHEMBL30153843 | 0.99 | ACHE (1.00) | ACHEBCHEEP300CYP3A4MAPT | |
| Berberine SCHEMBL15669190 | 0.99 | ACHE (1.00) | ACHEBCHEEP300CYP3A4MAPT | |
| Berberine SCHEMBL25632 | 0.99 | ACHE (1.00) | ACHEBCHEEP300CYP3A4MAPT | |
| Berberine SCHEMBL29354144 | 0.99 | ACHE (1.00) | ACHEBCHEEP300CYP3A4MAPT | |
| Berberine SCHEMBL2538316 | 0.98 | ACHE (0.98) | ACHEBCHEEP300CYP3A4MAPT | |
| Berberine SCHEMBL3686644 | 0.98 | ACHE (0.98) | ACHEBCHEEP300CYP3A4MAPT | |
| Berberine SCHEMBL21462194 | 0.98 | ACHE (0.98) | ACHEBCHEEP300CYP3A4MAPT | |
| Berberine SCHEMBL10709599 | 0.98 | ACHE (0.98) | ACHEBCHEEP300CYP3A4MAPT | |
| Berberine SCHEMBL153906 | 0.98 | ACHE (1.00) | ACHEBCHEEP300CYP3A4MAPT | |
| Berberine SCHEMBL4894622 | 0.98 | BCHE (0.98) | ACHEBCHEEP300CYP3A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250032455-A1 | NITROIMIDAZOLE FORMULATIONS | IRP Health Pty Ltd (AU) | 2025-01-30 | — | — | US | claimed |
| US-12171748-B2 | Nitroimidazole formulations | IRP Health Pty Ltd (AU) | 2024-12-24 | — | — | US | claimed |
| US-20210220335-A1 | NITROIMIDAZOLE FORMULATIONS | IRP Health Pty Ltd (AU) | 2021-07-22 | — | — | US | claimed |
| EP-3810137-A1 | NITROIMIDAZOLE FORMULATIONS | IRP Health Pty Ltd (AU) | 2021-04-28 | — | — | EP | claimed |
| CN-112543635-A | Nitroimidazole formulations | IRP健康股份有限公司 | 2021-03-23 | — | — | CN | claimed |
| WO-2019227149-A1 | NITROIMIDAZOLE FORMULATIONS | IRP Health Pty Ltd (AU) | 2019-12-05 | — | — | WO | claimed |
| WO-2011151359-A1 | COMBINED TREATMENT WITH A CHOLINESTERASE INHIBITOR AND A THIADIAZOLIDINEDIONE DERIVATIVE | NOSCIRA, S.A. (ES) | 2011-12-08 | — | — | WO | claimed |
| US-20100120747-A1 | COMBINATION OF A CHOLINESTERASE INHIBITOR AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-05-13 | — | — | US | claimed |
| EP-2040755-A1 | COMBINATION OF A CHOLINESTERASE INHIBITOR AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2009-04-01 | — | — | EP | claimed |
| WO-2007147883-A1 | COMBINATION OF A CHOLINESTERASE INHIBITOR AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-12-27 | — | — | WO | claimed |
| WO-1990005523-A2 | PHENANTHROLINEDICARBOXYLATE ESTERS, 4-AMINOQUINOLINE AND ISOQUINOLINE DERIVATIVES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE | THE UPJOHN COMPANY (US) | 1990-05-31 | — | — | WO | claimed |
| US-20250032455-A1 | NITROIMIDAZOLE FORMULATIONS | IRP Health Pty Ltd (AU) | 2025-01-30 | — | — | US | disclosed |
| US-12171748-B2 | Nitroimidazole formulations | IRP Health Pty Ltd (AU) | 2024-12-24 | — | — | US | disclosed |
| US-20210220335-A1 | NITROIMIDAZOLE FORMULATIONS | IRP Health Pty Ltd (AU) | 2021-07-22 | — | — | US | disclosed |
| EP-3810137-A1 | NITROIMIDAZOLE FORMULATIONS | IRP Health Pty Ltd (AU) | 2021-04-28 | — | — | EP | disclosed |
| US-20080038196-A1 | Standardization of botanical products utilizing biological activity as a marker | BEAVERS RANDY | 2008-02-14 | — | — | US | disclosed |
| WO-2007147883-A1 | COMBINATION OF A CHOLINESTERASE INHIBITOR AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-12-27 | — | — | WO | disclosed |
| US-20060228428-A1 | extract of at least one plant selected from Coptis chinensis Franch., Phellodendron genus plant, Sanguinaria canadensis and Chelidonium majus var. asiaticum; plant powdery mildew, anthracnose of pepper, damping-off of cucumber and gray mold rot of strawberry | KOREA BIO CHEMICAL CO., LTD (KR) | 2006-10-12 | — | — | US | disclosed |
| CN-1134436-C | Pharmaceutically available protoberberine salt derivatives, and protoberberine derivatives and salt thereof | — | 2004-01-14 | — | — | CN | disclosed |
| CN-1295573-A | Pharmaceutically available protoberberine salt derivatives, and protoberberine derivatives and salt thereof | HANWHA PETROCHEMICAL CO LTD (KR) | 2001-05-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210220335-A1 | NITROIMIDAZOLE FORMULATIONS | PHB1, COX5B, CYP3A5 | ACHE 1722/4885CHRM1 2679/4885BCHE 287/4885 |
| US-20080038196-A1 | Standardization of botanical products utilizing biological activity as a marker | TREH, CA12, MMP8 | ACHE 761/4885CHRM1 3550/4885BCHE 55/4885 |
| US-12171748-B2 | Nitroimidazole formulations | PHB1, COX5B, CYP3A5 | ACHE 1722/4885CHRM1 2679/4885BCHE 287/4885 |
| US-20100120747-A1 | COMBINATION OF A CHOLINESTERASE INHIBITOR AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | HTR6, AANAT, ACHE | ACHE 3/4885CHRM1 98/4885BCHE 14/4885 |
| US-20060228428-A1 | extract of at least one plant selected from Coptis chinensis Franch., Phellodendron genus plant, Sanguinaria canadensis and Chelidonium majus var. asiaticum; plant powdery mildew, anthracnose of pepper, damping-off of cucumber and gray mold rot of strawberry | COPS6, TIPARP, CPNE4 | ACHE 1682/4885CHRM1 1566/4885BCHE 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.